Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Pipeline

Home

Contact

Values

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Montserrat

Amplia Therapeutics Limited

Amplia CEO Dr Chris Burns recently joined Michael Frazis of Frazis Capital Partners for an in-depth interview on our lead FAK inhibitor, narmafotinib - and how it could transform the way chemotherapy is delivered to patients.

The discussion explores the urgent need for new therapies in pancreatic cancer, the hostile environment tumours create to block treatment, and how Amplia’s approach aims to improve chemotherapy outcomes. Dr Burns also shared updates on our ongoing clinical trials and outlined Amplia’s midterm strategy.

Frazis Capital Partners | Interview with Dr Chris Burns 